Ambient-temperature CO oxidation activity of Pd/CeO2 was found to increase by more than 20 times after thermal aging at 900 °C in air. Although the aging resulted in a significant sintering accompanied by a 92% loss of surface area from 92 to 7 m2·g−1, Pd metal dispersion was preserved at a high value (0.57). The analysis using transmission electron microscopy (TEM), high-angle annular dark-field (HAADF)-scanning transmission electron microscopy (STEM), extended X-ray absorption fine structure (EXAFS), and X-ray photoelectron spectroscopy (XPS) demonstrated that the activation is driven by metal−support interactions followed by phase transformation. Owing to the formation of Pd−O−Ce bonding at the PdO/CeO2 interface, Pd oxide species are highly dispersed into the surface structure of CeO2. The Pd oxide becomes unstable when the temperature reaches ≥800 °C, where thermodynamic PdO/Pd phase equilibrium is reached. Finally, the Pd−O−Ce surface moiety is fragmented into metallic Pd particles with a size of 1 to 2 nm, which provide active sites for CO oxidation.

The period following heart failure hospitalization (HFH) is a vulnerable time with high rates of death or recurrent HFH.OBJECTIVE To evaluate clinical characteristics, outcomes, and treatment response to vericiguat according to prespecified index event subgroups and time from index HFH in the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) trial. DESIGN, SETTING, AND PARTICIPANTSAnalysis of an international, randomized, placebo-controlled trial. All VICTORIA patients had recent (<6 months) worsening HF (ejection fraction <45%). Index event subgroups were less than 3 months after HFH (n = 3378), 3 to 6 months after HFH (n = 871), and those requiring outpatient intravenous diuretic therapy only for worsening HF (without HFH) in the previous 3 months (n = 801). Data were analyzed between May 2, 2020, and May 9, 2020.INTERVENTION Vericiguat titrated to 10 mg daily vs placebo. MAIN OUTCOMES AND MEASURESThe primary outcome was time to a composite of HFH or cardiovascular death; secondary outcomes were time to HFH, cardiovascular death, a composite of all-cause mortality or HFH, all-cause death, and total HFH. RESULTS Among 5050 patients in the VICTORIA trial, mean age was 67 years, 24% were women, 64% were White, 22% were Asian, and 5% were Black. Baseline characteristics were balanced between treatment arms within each subgroup. Over a median follow-up of 10.8 months, the primary event rates were 40.9, 29.6, and 23.4 events per 100 patient-years in the HFH at less than 3 months, HFH 3 to 6 months, and outpatient worsening subgroups, respectively. Compared with the outpatient worsening subgroup, the multivariable-adjusted relative risk of the primary outcome was higher in HFH less than 3 months (adjusted hazard ratio, 1.48; 95% CI, 1.27-1.73), with a time-dependent gradient of risk demonstrating that patients closest to their index HFH had the highest risk. Vericiguat was associated with reduced risk of the primary outcome overall and in all subgroups, without evidence of treatment heterogeneity. Similar results were evident for all-cause death and HFH. Addtionally, a continuous association between time from HFH and vericiguat treatment showed a trend toward greater benefit with longer duration since HFH. Safety events (symptomatic hypotension and syncope) were infrequent in all subgroups, with no difference between treatment arms.CONCLUSIONS AND RELEVANCE Among patients with worsening chronic HF, those in closest proximity to their index HFH had the highest risk of cardiovascular death or HFH, irrespective of age or clinical risk factors. The benefit of vericiguat did not differ significantly across the spectrum of risk in worsening HF.

No abstract

By applying a pulsed arc-plasma process, Pt nanoparticles were deposited from a Pt cathode onto CeO2 powders to study their structure and catalytic activity for CO oxidation. Highly dispersed uniform metallic Pt crystallites with the size of 2.6 ± 0.7 nm were obtained. Because of the highly dispersed metallic Pt nanoparticles suitable for CO chemisorption, the catalyst prepared by arc-plasma exhibited higher CO oxidation activity than those prepared by conventional wet impregnation. However, the catalyst was deactivated to a larger extent compared to the impregnated catalyst after thermal aging at 900 °C in a stream of 10% H2O in air.